10x Genomics, INC Schedule 13G passive stakes

ARK Investment Management LLC and Catherine D. Wood have filed an Amendment No. 3 to their Schedule 13G, reporting beneficial ownership of 10x Genomics, Inc. Class A Common Stock.

Vanguard Capital Management reports beneficial ownership of 6,166,597 shares, representing 5.24% of 10X Genomics Inc.'s common stock, as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.93% in 10X Genomics Inc. common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in 10X Genomics Inc. following an internal organizational realignment.

The Vanguard Group has filed an amended Schedule 13G, indicating it no longer holds a beneficial ownership stake in 10X Genomics Inc.

FMR LLC and Abigail P. Johnson reported a beneficial ownership of 15.6% of 10x Genomics, Inc.'s Class A Common Stock as of February 27, 2026.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 10.8% of 10x Genomics, Inc.'s Class A Common Stock as of December 31, 2025.

Amova Asset Management Americas, Inc. has filed an amendment to its Schedule 13G, reporting a 4.7% beneficial ownership stake in 10x Genomics, Inc. as of September 30, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing an 8.1% beneficial ownership stake in 10x Genomics, Inc.'s Class A Common Stock as of September 30, 2025.

ARK Investment Management LLC and Catherine D. Wood have disclosed a beneficial ownership of 10.39% in 10x Genomics, Inc. Class A Common Stock.

The Vanguard Group has increased its beneficial ownership in 10X Genomics Inc. to 11.6% of common stock, holding over 13.2 million shares.

Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. have reported a passive beneficial ownership of 4.7% in 10x Genomics, Inc. Class A common stock.

Nikko Asset Management Americas, Inc. has disclosed a 5.4% beneficial ownership stake in 10x Genomics, Inc. Class A common stock.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported a 2.7% beneficial ownership stake in 10x Genomics, Inc. Class A Common Stock.

FMR LLC and Abigail P. Johnson report a 10.3% beneficial ownership stake in 10x Genomics, Inc. Class A Common Stock as of July 31, 2025.

FMR LLC and Abigail P. Johnson have reported an 8.8% beneficial ownership stake in 10x Genomics, Inc.'s Class A Common Stock as of June 30, 2025.

Sumitomo Mitsui Trust Group, Inc. and Nikko Asset Management Co., Ltd. have jointly disclosed beneficial ownership of 5.4% of 10x Genomics, Inc.'s Class A common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.6% of the common stock of 10x Genomics, Inc. as of June 30, 2025.

ARK Investment Management LLC and its CEO, Catherine D. Wood, have jointly disclosed a significant beneficial ownership stake of 11.87% in 10x Genomics, Inc.'s Class A Common Stock.

Nikko Asset Management Americas, Inc., a subsidiary of Sumitomo Mitsui Trust Group, has disclosed a 5% beneficial ownership stake in 10x Genomics, Inc. Class A common stock as of March 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 5.2% of 10x Genomics, Inc.'s Class A Common Stock as of April 30, 2025.

FMR LLC and its control person, Abigail P. Johnson, have reported a continued beneficial ownership of 13.0% of 10x Genomics, Inc.'s Class A Common Stock as of March 31, 2025.

Japanese financial giants Sumitomo Mitsui Trust Group and Nikko Asset Management Co., Ltd. have jointly disclosed a significant 5% beneficial ownership stake in biotechnology company 10x Genomics, Inc.

Millennium Management LLC, along with its affiliates and Israel A. Englander, has reported a passive beneficial ownership of 5.1% in 10x Genomics, Inc.'s Class A Common Stock.